Viatris - M&A Summary and Business Overview

Life ScienceCompany

Viatris M&A Summary

Viatris has acquired 13 companies, including 2 in the last 5 years. A total of 3 acquisitions came from private equity firms. It has also divested 2 assets.

Viatris’ largest acquisition to date was in 2016, when it acquired Meda AB for $9.9B. It’s largest disclosed sale occurred in 2022, when it sold Viatris - Biosimilars to Biocon for $3.3B. Viatris has acquired in 5 different US states, and 6 countries. The Company’s most targeted sectors include life science (77%) and medical products (24%).

Viatris Business Overview

Where is Viatris headquartered?

Viatris is headquartered in Canonsburg, Pennsylvania.

What is Viatris’ revenue?

Viatris disclosed revenue of 15,427M USD for 2023 and 16,263M USD for 2022.

How many employees does Viatris have?

Viatris has 33,000 employees.

What sector is Viatris in?

Viatris is a life science company.

When was Viatris founded?

Viatris was founded in 1961.

M&A Summary

  • M&A Total Activity15
    • M&A Buy Activity13
    • M&A Sell Activity2
  • Total Sectors Invested 2
  • Total Countries Invested 6
  • M&A Buy/Sell Connections 13
  • M&A Advisors 8

Viatris

Viatris, Inc.

1000 Mylan Boulevard,
Canonsburg, Pennsylvania 15317
United States,
(724) 514-1800
www.viatris.com

Viatris is a generic and specialty pharmaceutical company. Viatris offers the industry's broadest and highest quality product portfolios, a robust product pipeline, and a global commercial footprint through operations in more than 90 countries. Viatris was founded in 1961 and is based in Canonsburg, Pennsylvania.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.2/yr) # 12 1 - - - - 13
vol $24.8B $723M $25.5B
Sell (0.4/yr) # - - - 1 - 1 2
vol $3.3B $3.3B
  15

Most Recent M&A

Company Date Value Type
Viatris - Over the Counter (OTC) Business 2024-07-03 - Divestiture
Canonsburg, Pennsylvania
Viatris - Biosimilars 2022-02-28 3.3B USD Divestiture
Canonsburg, Pennsylvania
Aspen Pharmacare Holdings Ltd. - Thrombosis Business 2020-09-08 723M EUR Divestiture
, United Kingdom
The Upjohn Company 2019-07-29 - Merger
Kalamazoo, Michigan
Cold-EEZE 2017-01-09 - Divestiture
Doylestown, Pennsylvania
Renaissance Acquisition - Specialty and Generics Business 2016-05-13 1.0B USD Divestiture
, Quebec
Meda AB 2016-02-10 9.9B USD Add-on Acquisition
Solna, Sweden · www.meda.se
Abbott - Non-U.S. Developed Markets Specialty and Branded Generics 2015-02-27 5.3B USD Divestiture
, United States
Famy Care Ltd. 2015-02-02 750M USD Add-on Acquisition
Mumbai, India · www.famycare.com
Agila Specialties Pvt. Ltd. 2013-12-04 1.8B USD Divestiture
Bengaluru, India
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 10 (77%) 18.4B (72%) 2 (100%) 3.3B (100%)
Medical Products 3 (23%) 7.1B (28%) - -
Total 13 $25.5B 2 $3.3B

By Geo

State/Country Buy Value Sell Value
United States 6 5.9B 2 3.3B
  Pennsylvania 1 - 2 3.3B
  Florida 2 - - -
  Michigan 1 - - -
  Illinois 1 550M - -
India 3 2.6B - -
Canada 1 1.0B - -
  Quebec 1 1.0B - -
Germany 1 5.5B - -
Sweden 1 9.9B - -
United Kingdom 1 723M - -
Domestic 6 (46%) 5.9B (23%) 2 (100%) 3.3B (100%)
Cross-border 7 (54%) 19.7B (77%) - -
Total 13 $25.5B 2 $3.3B

Top M&A Advisors

Financial Deals
Centerview Partners
3
Morgan Stanley
1
Credit Suisse Investment Banking
1
Legal Deals
Cravath, Swaine & Moore
4
NautaDutilh N.V.
2
Skadden, Arps, Slate, Meagher & Flom
1

Deal Values

buy # Total
> $1B 5 $23.5B
$100M to $1B 3 $2.0B
TOTAL $25.5B
Largest Meda AB
$9.9B (2016-02-10)
sell # Total
> $1B 1 $3.3B
TOTAL $3.3B
Largest Viatris - Biosimilars
$3.3B (2022-02-28)

M&A Connections

Deals
Acquired from
Investor(s)
23%
3 (23%)
Strategic(s)
54%
7 (54%)
Divested to
Strategic(s)
100%
2 (100%)

 Subscribe to unlock this and 204,613
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 196K M&A Transactions
  • 200K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 78K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.